Tyra Biosciences, Inc. (TYRA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 13.20 |
| Open | 14.35 |
| Bid | 13.30 x 900 |
| Ask | 13.65 x 4000 |
| Day's Range | 11.75 - 14.35 |
| 52 Week Range | 4.93 - 14.61 |
| Volume | |
| Avg. Volume | 43,198 |
| Market Cap | 561.225M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 18.73 |
| EPS (TTM) | 0.71 |
| Earnings Date | Nov 03, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for TYRA
Related Research
- Tyra Biosciences, Inc.Daily – Vickers Top Buyers & Sellers for 12/22/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
- PR Newswire
Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced the initiation of its SURF301 Phase 1/2 clinical study, with first patient dosed with TYRA-300. TYRA-300, the Company's lead product candidate stemming from its SNÅP platform, is an oral, FGFR3-selective inhibitor for the treatment of metastatic urothelial carcinoma of the bladder and urinary
- Zacks
How Much Upside is Left in Tyra Biosciences, Inc. (TYRA)? Wall Street Analysts Think 184%
The mean of analysts' price targets for Tyra Biosciences, Inc. (TYRA) points to an 184.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- PR Newswire
Tyra Biosciences to Present at Upcoming Investor Conferences
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that the Company will be presenting and hosting one-on-one meetings at the following conferences in November:
